Safety in the hypertriglyceridemia treatment with n-3 polyunsaturated fatty acids on glucose metabolism in subjects with type 2 diabetes mellitus;Seguridad en el tratamiento de la hipertrigliceridemia con n-3 ácidos grasos poliinsaturados en el metabolismo de la glucosa en pacientes con diabetes mellitus tipo 2

Nutricion Hospitalaria

Volumn 31, Issue 2, 2015, Pages 570-576

  Reis, Caio Eduardo Gonçalves ^a   Landim, Karla Câmara ^a   Nunes, Aline Costa Santos ^a   Dullius, Jane ^a  

^a UNIVERSITY OF BRASILIA   (Brazil)

Author keywords

Cardiovascular diseases; Diabetes mellitus; Lipid profile; N 3 PUFA; Triglycerides

Indexed keywords

GLUCOSE; OMEGA 3 FATTY ACID; UNSATURATED FATTY ACID;

COMPLICATION; HUMAN; HYPERTRIGLYCERIDEMIA; META ANALYSIS; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC);

DIABETES MELLITUS, TYPE 2; FATTY ACIDS, OMEGA-3; FATTY ACIDS, UNSATURATED; GLUCOSE; HUMANS; HYPERTRIGLYCERIDEMIA; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84923791604     PISSN: 02121611     EISSN: 16995198     Source Type: Journal    
DOI: 10.3305/nh.2015.31.2.7845     Document Type: Review

References (34)

1. Jung UJ, Torrejon C, Tighe AP, Deckelbaum RJ. N-3 Fatty acids and cardiovascular disease: mechanisms underlying beneficial effects. Am J Clin Nutr 2008;87(suppl):2003S–2009S.
2. Jacobson TA. Role of n-3 fatty acids in the treatment of hypertriacylglycerolemia and cardiovascular disease. Am J Clin Nutr 2008;87(suppl):1981S–1990S.
3. Mazzone T, Chait A, Plutzky J. Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies. Lancet 2008;371:1800–1809.
4. Smellie WSA. Hypertriglyceridaemia in diabetes. Br J Nutr 2006;333:1257–1260.
5. Pejic RN, Lee DT. Hypertriacylglycerolemia. J Am Board Fam Med 2006;19:310–316.
6. Cullen P. Evidence that triacylglycerols are an independent coronary heart disease risk factor. Am J Cardiol 2000;86:943–949.
7. Schwellenbach LJ, Olson KL, Mcconnell KJ, Stolcpart RS, Nash JD, Merenich JA. The triacylglycerol-lowering effects of a modest dose of docosahexaenoic acid alone versus in combination with low dose eicosapentaenoic acid in patients with coronary artery disease and elevated triacylglycerols. J Am Coll Nutr 2006;25:480–485.
8. Oh RC, Lanier JB. Management of hypertriacylglycerolemia. Am Fam Physician 2007;75:1365–1371.
9. De Caterina R, Madonna R, Bertolotto A, Schmidt EB. N-3 fatty acids in the treatment of diabetic patients-Biological rationale and clinical data. Diabetes Care 2007;30:1012–1026.
10. Hartweg J, Farmer AJ, Perera R, Holman RR, Neil HAW. Meta-analysis of the effects of n-3 polyunsaturated fatty acids on lipoproteins and other emerging lipid cardiovascular risk markers in patients with type 2 diabetes. Diabetologia 2007;50:1593–1602.
11. Hartweg J, Perera R, Montori V, Dinneen S, Neil HAW, Farmer A. Omega-3 polyunsaturated fatty acids (PUFA) for type 2 diabetes mellitus. Cochrane Database Syst Rev 2008;23:CD003205.
12. Rudkowska I. Fish oils for cardiovascular disease: Impact on diabetes. Maturitas 2010;67:25–28.
13. Schectman G, Kaul S, Kissebah AH. Effect of fish oil concentrate on lipoprotein composition in NIDDM. Diabetes 1988;37:1567–1573.
14. Glauber H, Wallace P, Griver K, Brechtel G. Adverse Metabolic Effect of Omega-3 Fatty-Acids in Non-Insulin-Dependent Diabetes-Mellitus. Ann Intern Med 1998;108:663–668.
15. Kasim SE, Stern B, Khilnani S, Mclin P, Baciorowski S, Jen KL. Effects of omega-3 fish oils on lipid metabolism, glycemic control, and blood pressure in type II diabetic patients. J Clin Endocrinol Metab 1998;67:1–5.
16. Mostad IL, Bjerve KS, Bjorgaas MR, Lydersen S, Grill V. Effects of n–3 fatty acids in subjects with type 2 diabetes: reduction of insulin sensitivity and time-dependent alteration from carbohydrate to fat oxidation. Am J Clin Nutr 2006;84:540–550.
17. Wu JH, Micha R, Imamura F, et al. Omega-3 fatty acids and incident type 2 diabetes: a systematic review and meta-analysis. Br J Nutr 2012;107(Suppl 2):S214–S227.
18. Annuzzi G, Rivellese A, Capaldo B. A controlled study on the effects of n-3 fatty acids on lipid and glucose metabolism in non-insulin-dependent diabetic patients. Atherosclerosis 1991;87:65–73.
19. Boberg M, Pollare T, Siegbahn A, Vessby B. Supplementation with n-3 fatty acids reduces triacylglycerols but increases PAI-1 in non-insulin-dependent diabetes mellitus. Eur J Clin Invest 1992;22:645–650.
20. Axelrod L, Camuso J, Williams E, Kleinman K, Briones E, Schoenfeld D. Effects of a small quantity of omega-3 fatty acids on cardiovascular risk factors in NIDDM. A randomized, prospective, double-blind, controlled study. Diabetes Care 1994;17:37–44.
21. Sirtori C, Paoletti R, Mancini M, et al. N-3 fatty acids do not lead to an increased diabetic risk in patients with hyperlipidemia and abnormal glucose tolerance. Italian Fish Oil Multicenter Study. Am J Clin Nutr 1997;65:1874–1881.
22. Goh YK, Jumpsen JA, Ryan EA, Clandinin MT. Effect of w3 fatty acid on plasma lipids, cholesterol and lipoprotein fatty acid content in NIDDM patients. Diabetologia 1997;40:45–52.
23. Sirtori CR, Crepaldic G, Manzato E, et al. One-year treatment with ethyl esters of n-3 fatty acids in patients with hypertiglyceridemia and glucose intolerance: reduced triacylglycerolmia, total cholesterol and increased HDL-c without glycemic alterations. Atherosclerosis 1998;137:419–427.
24. Luo J, Rizkalla SW, Vidal H, et al. Moderate intake of n-3 fatty acids for 2 months has no detrimental effect on glucose metabolism and could ameliorate the lipid profile in type 2 diabetic men. Results of a controlled study. Diabetes Care 1998;21(5):717–724.
25. Woodman RJ, Mori TA, Burke V, Puddey IB, Watts GF, Beilin LJ. Effects of purified eicosapentaenoic and docosahexaenoic acids on glycemic control, blood pressure, and serum lipids in type 2 diabetic patients with treated hypertension. Am J Clin Nutr 2002;76:1007–1015.
26. Ouguerram K, Maugeais C, Gardette J, Magot T, Krempf M. Effect of n-3 fatty acids on metabolism of apoB100-containing lipoprotein in type 2 diabetic subjects. Br J Nutr 2006; 96:100–106.
27. Garg ML, Blake RJ, Clayton E, et al. Consumption of an n-3 polyunsaturated fatty acid-enriched dip modulates plasma lipid profile in subjects with diabetes type II. Eur J Clin Nutr 2007;61:1312–1317.
28. Kabir M, Skurnik G, Naour N, et al. Treatment for 2 mo with n-3 polyunsaturated fatty acids reduces adiposity and some atherogenic factors but does not improve insulin sensitivity in women with type 2 diabetes: a randomized controlled study. Am J Clin Nutr 2007;86:1670–1679.
29. Shidfar F, Keshavarz A, Hosseyni S, Ameri A, Yarahmadi S. Effects of omega-3 fatty acid supplements on serum lipids, apolipoproteins and malondialdehyde in type 2 diabetes patients. East Mediterr Health J 2008;14:305–313.
30. De Luis DA, Conde R, Aller R, et al. Effect of omega-3 fatty acids on cardiovascular risk factors in patients with type 2 diabetes mellitus and hypertriacylglycerolemia: an open study. Eur Rev Med Pharmacol Sci 2009;13:51–55.
31. Crochemore IC, Souza AF, de Souza AC, Rosado EL. ω-3 polyunsaturated fatty acid supplementation does not influence body composition, insulin resistance, and lipemia in women with type 2 diabetes and obesity. Nutr Clin Pract 2012;27(4):553–560.
32. De Caterina R, Madonna R, Bertolotto A, Schmidt EB. N-3 fatty acids in the treatment of diabetic patients-Biological rationale and clinical data. Diabetes Care 2007;30:1012–1026.
33. Martin de Santa Olalla L, Sanchez Muniz FJ, Vaquero MP. N-3 fatty acids in glucose metabolism and insulin sensitivity. Nutr Hosp 2009;24(2):113–127.
34. Akinkuolie AO, Ngwa JS, Meigs JB, Djousse L. Omega-3 polyunsaturated fatty acid and insulin sensitivity: a meta-analysis of randomized controlled trials. Clin Nutr 2011;30(6):702–707.